Normal initial fees of 3-5% waived until end of December Award-winning Enterprise Investment Scheme (EIS) and Venture Capital Trust (VCT) specialist, Calculus Capital, is waiving initial fees on its VCT until the end of November. The VCT is aiming to deliver an annual tax-free dividend of 4.5%, as well as capital growth. Earlier this year Calculus … Continued
Mo enables individuals, teams and organisations to capture, celebrate and elevate moments at work by becoming the destination for people to share and engage in what is meaningful to them at work. Mo believes meaningful moments have the power to connect people, improve employee engagement and create a culture that improves business performance. Calculus Capital … Continued
Calculus has long been a supporter of the life sciences sector. In April we wrote about how many of our healthcare companies had quickly pivoted their resources to help play their part in the fight against COVID-19. Over the past few months they have been making important contributions which we would like to highlight below. … Continued
Open Orphan/hVIVO Signs Contract with UK Government for the Development of a COVID-19 Human Challenge Study Model COVID-19 human challenge study model to safely speed up development of an efficacious vaccine. hVIVO has the world’s leading portfolio of 8 human challenge study models developed to date and has safely run more human challenge studies than any other company globally … Continued
New agreement to develop and commercialise ready-to-administer medicine The agreement builds on Hikma and Arecor’s first product co-development agreement, which was announced on 9 January 2020 London and Cambridge, October 20, 2020 Hikma Pharmaceuticals PLC (Hikma or the Group), the multinational pharmaceutical company, and Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier … Continued
In October, Oxford BioTherapeutics (OBT) received a milestone payment from Boehringer Ingelheim (BI) for the progression of the first bispecific oncology drug candidate, developed under their collaboration, into Phase I clinical trials. In addition, OBT established a new, expanded collaboration with BI, whereby OBT will validate certain novel oncology drug targets that are compatible for … Continued
Realisation in Genedrive achieved an average of 2x return for investors, while Yourgene netted an average of 1.64x return Both companies are listed on AIM, and benefitted from significant growth in the share price during the current pandemic, by refocusing their resources to COVID-19 testing Genedrive is a molecular diagnostics company developing and commercialising a … Continued
The Calculus Creative Content EIS Fund has invested in Home Team, a production company founded by Dominic Buchanan and Bennett McGhee, it was announced today by the Fund’s manager Calculus Capital and Stargrove Pictures, its media adviser. HOME TEAM will operate in the international film & television space, with a focus on the development and production … Continued
Scancell has secured funding from Innovate UK, the UK’s Innovation Agency, through the ‘UK Research and Innovation (UKRI) Ideas to Address COVID-19’ funding strand The funding will be used to initiate a Phase 1 clinical trial (“COVIDITY”) during 2021. The project is being led by Professor Lindy Durrant, Chief Scientific Officer of Scancell and Professor … Continued
After a successful first year, investing in four diversified creative companies, the second iteration of the Calculus Creative Content EIS Fund is open for subscription Launched in association with the BFI, this is a new breed of EIS Fund in the media sector. It will focus on building and growing companies involved in a broad … Continued